Invectys
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
27 Rue Du Faubourg Saint Jacques, Paris,...Phone Number
+33 181800520Website
www.invectys.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Invectys
Invectys Inc. is a biopharmaceutical company based in Houston, Texas, focused on developing innovative immunotherapy approaches to treat cancer. Founded in 2010, the company leverages its HLA-G platform and universal tumor antigen telomerase (TERT) to enhance the anti-tumor capacity of the immune system. Invectys targets a wide range of cancers and is supported by both French and international private investors. The company is currently engaged in clinical trials, including its IVS-3001 CAR-T cell therapy for renal cell carcinoma.Explore more
Invectys Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Invectys your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Invectys had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Invectys, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Invectys launches new products
Check out if Invectys is spiking on competitors!
Check if Invectys has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Invectys
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Invectys has new funding data
Earning: See what the market has to say on Invectys recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Invectys as Masked Content
Find 3 more new buyers
Compare Similar Companies to Invectys
Compare insights from companies similar to Invectys, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Invectys is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Invectys is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Invectys.
Invectys Tech Stack
A closer look at the technologies used by Invectys
See more technologies
Most Recent Scoops
Executive Move
Pain Point
Project
A high-level source in product development has indicated that the organization is planning to remediate challenges related to web development.
Collaboration/Web Apps, Application Development, Product Development, Website
Project
A high-level source in product development has indicated that the organization has completed initiatives related to quality assurance within the last nine months.
Quality Assurance, Product Development
Project
Invectys News & Media
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership
Houston, TX, USA, July 13, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company developing novel therapies for the treatment of advanced cancers, today announces it has initiated the clinical trial of its lead CAR-T program, IVS-3001, in solid tumors. The Company also announces the appointment of Dr. Jake Kushner, M.D., as its new CEO.Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumorsInvectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumorsINVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT
HOUSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant and scalable process for human leukocyte antigen (HLA)-G targeted chimeric antigen receptor (CAR) T cell therapy for solid tumors.
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Invectys
Sign Up For FreeTo access detailed company insights
Invectys Inc. is a biopharmaceutical company based in Houston, Texas, focused on developing innovative immunotherapy approaches to treat cancer. Founded in 2010, the company leverages its HLA-G platform and universal tumor antigen telomerase (TERT) to enhance the anti-tumor capacity of the immune system. Invectys targets a wide range of cancers and... Read More
